|Articles|April 8, 2004

INGN 241 in phase II clinical trial

Source: www.biotechnologyhealthcare.com Austin, Texas ? Introgen Therapies announced initiation of a Phase II clinical trial of INGN 241 in patients with metastatic melanoma.


Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.